Anavex Life Sciences (AVXL) said Tuesday it filed a marketing authorization application with the European Medicines Agency for blarcamesine to treat Alzheimer's disease.
Anavex said that blarcamesine, which is administered orally once a day, showed "clinically meaningful improvement over 48 weeks with primary endpoint ADAS-Cog13 score being larger than 2 points."
"This suggests superior numerical clinical efficacy compared to approved therapies while also slowing neurodegeneration in early [Alzheimer's disease] patients," the company said.
This is the first marketing authorization filing for the drug, Anavex said.
Anavex shares were more than 13% higher in premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。